Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model
Skye Bioscience, Inc. (SKYE)
Company Research
Source: GlobeNewswire
Nimacimab shows comparable weight loss to monlunabant and tirzepatide alone, and an additive effect in combination with tirzepatide, in diet-induced obesity modelNew in vitro data demonstrates superior potency of nimacimab’s differentiated and favorable mechanism of inhibition versus monlunabant Nimacimab Phase 2a CBeyond™ top-line randomized data expected late Q3/early Q4 2025 SAN DIEGO, April 15, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced new preclinical data for its novel CB1 antibody, nimacimab. In a murine diet-induced obesity (DIO) model, after 25 days of treatment, results demonstrated: Greater than 30% weight loss when nimacimab was combined with the dual GLP-1/GIP agonist, tirzepatideNimacimab alone demonstrated 23.5% weight loss, comparable to monlunabant and tirzepatide alo
Show less
Read more
Impact Snapshot
Event Time:
SKYE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SKYE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SKYE alerts
High impacting Skye Bioscience, Inc. news events
Weekly update
A roundup of the hottest topics
SKYE
News
- SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law FirmGlobeNewswire
- Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of January 16, 2026 in Skye Bioscience, Inc. Lawsuit - SKYEPR Newswire
- Bragar Eagel & Squire, P.C. Urges DeFi, Skye Bioscience, and Perrigo Investors to Contact the Firm Regarding their RightsGlobeNewswire
- Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Skye Bioscience, Inc. (SKYE) ShareholdersGlobeNewswire
- SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud LawsuitPR Newswire
SKYE
Earnings
- 11/10/25 - Beat
SKYE
Sec Filings
- 12/16/25 - Form SCHEDULE
- 11/10/25 - Form 8-K
- 11/10/25 - Form 10-Q
- SKYE's page on the SEC website